AXSM
Axsome Therapeutics, Inc.
Next earnings Aug 3, 2026 · consensus $-0.90 EPS, $224M rev
Last earnings +8.3% on 2026-05-04
$244.31
▲ +1.32%$244.31▲ +136.37%
over 1Y
L $100.39H $255.17
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.3%
1W+2.9%
1M+10.0%
3M+45.0%
YTD+36.7%
1Y+136.4%
Buy
Conviction
Horizon
Long (>12mo)
Street · 27 analysts
Buy
CNS biopharma scaling fast — revenue +65.5% to $638M across three launched drugs, with losses narrowing and a deep pipeline.
Revenue $638M · FY2025
Axsome has transitioned from a clinical-stage story into a commercial-stage CNS company with real, accelerating revenue. FY2025 revenue grew 65.5% to $638M behind three FDA-approved products — AUVELITY (the first oral NMDA antagonist for major depressive disorder), SUNOSI (excessive daytime sleepiness), and the newly launched SYMBRAVO (acute migraine). Crucially, the losses are shrinking even as the company invests: net loss narrowed 36% to -$183M and the operating loss improved 41% to -$167M, while operating cash burn fell to -$93.4M. That is the right trajectory for a scaling specialty-pharma launch.
The pipeline adds optionality on top of the in-market franchise: AUVELITY is being developed for Alzheimer's disease agitation, with additional programs in narcolepsy, fibromyalgia and ADHD. R&D held roughly flat at $183M, indicating commercial scale-up is funding itself rather than crowding out development.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:46 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $50.0M | $271M | $386M | $638M |
| Gross profit | — | — | — | — | — |
| Operating income | -$125M | -$180M | -$232M | -$281M | -$167M |
| Net income | -$130M | -$187M | -$239M | -$287M | -$183M |
| Diluted EPS | -$3.47 | -$4.60 | -$5.27 | -$5.99 | -$3.68 |
| Net margin | — | -374.0% | -88.4% | -74.5% | -28.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$12.4B
EV / EBITDA—
EV / Sales19.5
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-1.5%
FCF yield-0.7%
Quality & risk
ROIC (est.)-47.7%
Free cash flow-$93.9M
Total debt$188M
Net cash$135M
Altman Z-Score10.38 safe
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+4.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-07-012026-07-01open ↗144Filing2026-07-01open ↗4Period ending 2026-06-102026-06-11open ↗144Filing2026-06-11open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗4Period ending 2026-06-082026-06-10open ↗144Filing2026-06-10open ↗144Filing2026-06-10open ↗144Filing2026-06-10open ↗144Filing2026-06-09open ↗
Frequently asked
- Is Axsome Therapeutics, Inc. (AXSM) a buy?
- AXSM currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. CNS biopharma scaling fast — revenue +65.5% to $638M across three launched drugs, with losses narrowing and a deep pipeline.
- What is Axsome Therapeutics, Inc.'s quality score?
- AXSM scores 50.04505914760421/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001579428, latest 10-Q filed 2026-05-04) · EODHD · Proprietary analysis · as of 6/21/2026, 8:46:33 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.